Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) In Head-to-Head DURATION-3 Study
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus® (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.
generic viagra online
The 2009 AMSA National Leadership Development Seminar, Australia
The AMSA National Leadership Development Seminar will be held from the 7th to the 9th of September 2009.
News of the day
Acceleron To Present ACE-031 Preclinical Study Results As Treatment For Loss Of Muscle Mass And Function
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced it will provide three oral presentations on data from its ACE-031 program at the Endocrine Society"s 91st Annual Meeting to be held in Washington, DC from June 10-13, 2009. The presentations will provide results from preclinical studies highlighting the effects of its lead investigational product for treating diseases involving the loss of muscle mass and function.
Oncology

Predicting Tamoxifen Resistance In Patients

Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumor cells are a major cause of death. In a study in this month"s Molecular and Cellular Proteomics, researchers have uncovered a protein profile that may accurately predict whether a cancer will be tamoxifen resistant. Arzu Umar and colleagues in the Netherlands and Washington examined thousands of tumor cells taken from 51 tamoxifen therapy-sensitive and therapy-resistant tumors using a combination of proteomic and mass-spectrometry approaches. Their analysis revealed a set of 100 proteins that were expressed at different abundance levels in the two tumor groups, highlighting a potential profile for tamoxifen resistance. In addition, they analyzed the most significantly altered protein, called extracellular matrix metalloproteinase inducer, or EMMPRIN, in a separate set 156 breast tumor tissue samples. EMMPRIN levels were higher in tamoxifen-resistant tumors and significantly associated with an earlier tumor progression following first line tamoxifen treatment and poor clinical outcome, suggesting EMMPRIN may be a reliable marker for highly aggressive breast cancer. While further work with additional samples will be needed to validate these potential markers, the authors note this profile could be clinically useful, especially considering their approach used minute amounts of tissue samples, making it applicable at even the earliest tumor stages. Notes: From the study: "Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer" by Arzu Umar, Hyuk Kang, Annemieke Timmermans, Maxime P. Look, Marion E. Meijer-van Gelder, Michael A. den Bakker, Navdeep Jaitly, John W. M. Martens, Theo M. Luider, John A. Foekens and Ljiljana Pa a-Toli Article Link: http://www.mcponline.org/cgi/content/full/8/4/720 Corresponding Authors: Arzu Umar, Erasmus Medical Center, Rotterdam, Netherlands; Ljiljana Pasa-Tolic, Pacific Northwest National Laboratory, Richland, Washington. Nick Zagorski American Society for Biochemistry and Molecular Biology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009